title: Low-dose transdermal testosterone augmentation therapy improves depression severity in women.
abstract: BACKGROUND
  Inadequate response to antidepressant monotherapy in women with major depressive disorder is common. Testosterone administration has been shown to be an effective augmentation therapy in depressed hypogonadal men with selective serotonin reuptake inhibitor-resistant depression. However, the effects of low-dose testosterone as augmentation therapy in women with treatment-resistant depression have not been studied.
  
  
  METHODS
  Low-dose transdermal testosterone (300 mcg/day, Intrinsa, Procter and Gamble Pharmaceuticals) was administered to nine women with treatment-resistant depression in an 8 week open-label pilot protocol.
  
  
  RESULTS
  There was a statistically significant improvement in mean Montgomery-Asberg Depression Rating Scale (MADRS) scores at 2 weeks, sustained through the 8 week period. Two-thirds of subjects achieved a response to the treatment (decrease in MADRS score of 250%) and 33% achieved remission (final MADRS score <10) after 8 weeks of therapy. Mean levels of fatigue, as measured by the MADRS lassitude item, significantly decreased at all time points with a mean 38% decrease from baseline to 8 weeks.
  
  
  CONCLUSIONS
  These preliminary pilot data suggest that low-dose transdermal testosterone may be an effective augmentation therapy in women with treatment-resistant depression. Further studies are warranted. CNS Spectr. 2009;14(12):688-694
authors.affiliation: Neurendocrine Research Program in Women's Health, Neuendocrine Unit, Massachusetts General Hospital, Boston, MA, USA. kkmiller@partners.org
authors.forename: Karen K
authors.initials: KK
authors.lastname: Miller
authors.forename: Roy H
authors.initials: RH
authors.lastname: Perlis
authors.forename: George I
authors.initials: GI
authors.lastname: Papakostas
authors.forename: David
authors.initials: D
authors.lastname: Mischoulon
authors.forename: Dan V
authors.initials: DV
authors.lastname: Losifescu
authors.forename: Danielle J
authors.initials: DJ
authors.lastname: Brick
authors.forename: Maurizio
authors.initials: M
authors.lastname: Fava
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D000728:Androgens / Q000008:administration & dosage* / Q000097:blood; D000928:Antidepressive Agents / Q000494:pharmacology; D003863:Depression / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011863:Radioimmunoassay / Q000379:methods; D012044:Regression Analysis; D013739:Testosterone / Q000008:administration & dosage* / Q000097:blood; D013997:Time Factors
chemical_list: D000728:Androgens; D000928:Antidepressive Agents; D013739:Testosterone
references.citation: J Clin Psychiatry. 2005 Jan;66(1):85-93
references.pmid: 15669893
references.citation: J Clin Psychiatry. 2000 May;61(5):378-81
references.pmid: 10847314
references.citation: Arch Intern Med. 2005 Jul 25;165(14):1582-9
references.pmid: 16043675
references.citation: N Engl J Med. 2000 Sep 7;343(10):682-8
references.pmid: 10974131
references.citation: J Clin Psychiatry. 1999 Apr;60(4):221-5
references.pmid: 10221281
references.citation: J Clin Psychiatry. 2002;63 Suppl 5:13-6; discussion 23-5
references.pmid: 11964136
references.citation: J Clin Endocrinol Metab. 2000 Aug;85(8):2839-53
references.pmid: 10946892
references.citation: Am J Psychiatry. 2002 Aug;159(8):1427-9
references.pmid: 12153840
references.citation: J Clin Endocrinol Metab. 2005 Sep;90(9):5226-33
references.pmid: 16014407
references.citation: J Clin Psychiatry. 2003;64 Suppl 14:30-4
references.pmid: 14658933
references.citation: J Clin Endocrinol Metab. 2005 Mar;90(3):1428-33
references.pmid: 15613421
references.citation: Metabolism. 1972 Jul;21(7):667-88
references.pmid: 4562220
references.citation: J Clin Psychopharmacol. 2008 Apr;28(2):156-65
references.pmid: 18344725
references.citation: Am J Psychiatry. 2003 Jan;160(1):105-11
references.pmid: 12505808
references.citation: Ann Clin Psychiatry. 2007 Jul-Sep;19(3):153-9
references.pmid: 17729016
references.citation: Menopause. 2006 Mar-Apr;13(2):202-11
references.pmid: 16645534
references.citation: J Clin Psychiatry. 2007 Jun;68(6):826-31
references.pmid: 17592905
references.citation: J Affect Disord. 1999 Dec;56(2-3):201-8
references.pmid: 10701478
references.citation: CNS Spectr. 2006 Feb;11(2):93-102
references.pmid: 16520686
references.citation: J Clin Invest. 1967 May;46(5):891-902
references.pmid: 6025489
references.citation: J Behav Ther Exp Psychiatry. 2004 Mar;35(1):49-55
references.pmid: 15157817
references.citation: Menopause. 2006 Sep-Oct;13(5):770-9
references.pmid: 16932240
references.citation: Arch Gen Psychiatry. 2000 Feb;57(2):141-7; discussion 155-6
references.pmid: 10665616
references.citation: Psychopharmacol Bull. 1997;33(4):755-60
references.pmid: 9493488
references.citation: J Clin Endocrinol Metab. 2006 May;91(5):1683-90
references.pmid: 16478814
references.citation: J Clin Endocrinol Metab. 1996 Oct;81(10):3578-83
references.pmid: 8855804
references.citation: J Clin Psychopharmacol. 2004 Aug;24(4):379-85
references.pmid: 15232328
references.citation: Prog Neuropsychopharmacol. 1979;3(4):429-33
references.pmid: 400999
references.citation: Arch Gen Psychiatry. 2005 Jun;62(6):593-602
references.pmid: 15939837
references.citation: N Engl J Med. 2008 Nov 6;359(19):2005-17
references.pmid: 18987368
references.citation: Obstet Gynecol. 2005 May;105(5 Pt 1):944-52
references.pmid: 15863529
references.citation: J Clin Endocrinol Metab. 2004 Feb;89(2):525-33
references.pmid: 14764757
references.citation: Am J Psychiatry. 2006 Jan;163(1):28-40
references.pmid: 16390886
references.citation: Menopause. 2006 May-Jun;13(3):387-96
references.pmid: 16735935
references.citation: J Clin Endocrinol Metab. 1970 Nov;31(5):556-64
references.pmid: 4248490
references.citation: Maturitas. 1981 Dec;3(3-4):215-23
references.pmid: 7334933